Biocon Limited
NSE: BIOCON
Employs 4,155 permanent employees and workers, −1.2% on the year before, as filed for the year to 31 Mar 2026 on a group basis. Revenue in the quarter to 31 Dec 2024 was ₹563 cr.
Headcount
Annual, from the BRSR filed with NSE (as of 31 March each year)
| As of | Scope | Permanent | Change (%) | Contract / other | Change (%) |
|---|---|---|---|---|---|
| 31 Mar 2022 | Group | 8,789 | — | 2,156 | — |
| 31 Mar 2023 | Group | 9,698 | 909(10.3%) | 1,832 | −324(15.0%) |
| 31 Mar 2024 | Group | 9,805 | 107(1.1%) | 2,194 | 362(19.8%) |
| 31 Mar 2025 | Group⚠ | 4,204 | −5,601(57.1%) | 1,132 | −1,062(48.4%) |
| 31 Mar 2026 | Group | 4,155 | −49(1.2%) | 1,106 | −26(2.3%) |
- ⚠Unusually large change — often a change in what the company counts.
Permanent = permanent employees + permanent workers, as defined in SEBI's BRSR. "Standalone" figures cover the listed company alone and exclude its subsidiaries.
Financials (₹ cr)
| Period | Revenue (₹ cr) | Change (%) | Employee cost (₹ cr) | Change (%) | Net profit (₹ cr) | Change (%) | Flags |
|---|---|---|---|---|---|---|---|
| Quarter ended 31 Dec 2024 | 563 | 37(7.1%) | 132 | 7(5.2%) | 584 | 581(18150.0%) | |
| Quarter ended 30 Sept 2024 | 525 | 15(2.9%) | 125 | 6(4.8%) | 3 | 2(255.6%) | |
| Quarter ended 30 Jun 2024 | 511 | −22(4.1%) | 120 | 3(2.5%) | 1 | −13(93.6%) | |
| Quarter ended 31 Mar 2024 | 533 | −30(5.4%) | 117 | −1(0.7%) | 14 | −10(41.7%) | |
| Quarter ended 31 Dec 2023 | 563 | 44(8.5%) | 118 | 5(4.5%) | 24 | −11(30.8%) | |
| Quarter ended 30 Sept 2023 | 519 | 6(1.1%) | 113 | 7(6.7%) | 35 | −12(25.5%) | |
| Quarter ended 30 Jun 2023 | 513 | 7(1.3%) | 105 | −2(2.0%) | 47 | −1,764(97.4%) | |
| Quarter ended 31 Mar 2023 | 507 | −48(8.7%) | 108 | −4(3.5%) | 1,811 | 1,776(5044.3%) | |
| Quarter ended 31 Dec 2022 | 555 | 37(7.2%) | 112 | 18(18.9%) | 35 | −3(7.6%) | |
| Quarter ended 31 Mar 2022 | 518 | 45(9.4%) | 94 | −3(3.0%) | 38 | 13(49.4%) | ⚠ |
| Quarter ended 31 Dec 2021 | 473 | 108(29.7%) | 97 | 0(0.2%) | 26 | 32(486.4%) | ⚠ |
| Quarter ended 30 Sept 2021 | 365 | −18(4.7%) | 97 | 16(19.6%) | -7 | −36(122.7%) | ⚠ |
| Quarter ended 30 Jun 2021 | 383 | −109(22.1%) | 81 | −16(16.8%) | 29 | −39(57.0%) | ⚠ |
| Quarter ended 31 Mar 2021 | 492 | 36(7.8%) | 97 | −10(9.3%) | 68 | 35(105.2%) | ⚠ |
| Quarter ended 31 Dec 2020 | 456 | −104(18.6%) | 107 | 5(5.1%) | 33 | −62(65.3%) | ⚠ |
| Quarter ended 30 Sept 2020 | 560 | 39(7.5%) | 102 | 17(20.6%) | 95 | 10(12.0%) | ⚠ |
| Quarter ended 30 Jun 2020 | 521 | 38(7.9%) | 84 | −6(6.1%) | 85 | −17(17.0%) | ⚠ |
| Quarter ended 31 Mar 2020 | 482 | −19(3.8%) | 90 | 2(2.4%) | 102 | −19(15.3%) | ⚠ |
| Quarter ended 31 Dec 2019 | 501 | −23(4.3%) | 88 | 3(3.4%) | 121 | 15(13.8%) | ⚠ |
| Quarter ended 30 Sept 2019 | 524 | 43(9.0%) | 85 | 3(3.3%) | 106 | −6(5.2%) | ⚠ |
| Quarter ended 30 Jun 2019 | 481 | −283(37.1%) | 82 | −57(41.1%) | 112 | 41(58.7%) | ⚠ |
| Quarter ended 31 Mar 2019 | 764 | 24(3.3%) | 140 | 9(7.2%) | 71 | −2(3.0%) | ⚠ |
| Quarter ended 31 Dec 2018 | 740 | 31(4.3%) | 130 | 1(0.9%) | 73 | −47(39.3%) | ⚠ |
| Quarter ended 30 Sept 2018 | 709 | — | 129 | — | 120 | — | ⚠ |